Antengene’s multiple myeloma therapy receives approval in Hong Kong
Antengene has received approval in Hong Kong for a new drug application (NDA) for Xpovio (selinexor) to treat multiple myeloma (R/R MM).
Antengene has received approval in Hong Kong for a new drug application (NDA) for Xpovio (selinexor) to treat multiple myeloma (R/R MM).
What's Your Reaction?
